Core Viewpoint - The company, HAPO Pharmaceutical-B (02142), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will repurchase 100,000 shares at a total cost of HKD 1.337 million [1] - The buyback price per share ranges from HKD 13.18 to HKD 13.53 [1] - The buyback is scheduled for November 28, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年11月28日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包 ...

Core Viewpoint - Heptagon Pharmaceuticals-B (02142.HK) has seen a price increase of over 4%, currently trading at 14.22 HKD with a transaction volume of 27.84 million HKD [2] Summary by Category - **Stock Performance** - Heptagon Pharmaceuticals-B's stock rose by 4.25% [2] - The current trading price is 14.22 HKD [2] - The transaction volume reached 27.84 million HKD [2]

Core Viewpoint - Heptagon Pharmaceuticals (02142) has seen a stock increase of over 4%, currently trading at 14.22 HKD, with a transaction volume of 27.84 million HKD, following the announcement of an updated global strategic collaboration with AstraZeneca established in March 2025 [1] Group 1: Collaboration Details - The collaboration aims to jointly discover and develop next-generation biotherapies, including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] - AstraZeneca will nominate R&D projects annually for the next four years, highlighting the deepening partnership between the two companies [1] - Heptagon Pharmaceuticals is eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of the licensed projects, consistent with the financial framework established in March 2025 [1]

Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) has increased by over 4%, reaching HKD 14.22, with a trading volume of HKD 27.84 million, following the announcement of an updated global strategic collaboration with AstraZeneca [1] Group 1: Collaboration Details - HAPO Pharmaceutical announced an update to its global strategic collaboration with AstraZeneca, established in March 2025, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] - Under the agreement, AstraZeneca will nominate R&D projects annually for the next four years, demonstrating the deepening of the partnership [1] - HAPO Pharmaceutical will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of the licensed projects, consistent with the financial framework established in March 2025 [1]

Core Insights - The announcement highlights the deepening global strategic collaboration between Heptares Therapeutics and AstraZeneca established in March 2025 [1] - The partnership focuses on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] Collaboration Details - AstraZeneca will nominate research projects to Heptares Therapeutics annually over the next four years, demonstrating the ongoing commitment to the partnership [1] - Heptares Therapeutics is eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1]

Group 1 - Fubo Group (03738) increased by over 9% after launching AI music detection services on November 21 [1] - Hard Egg Innovation (00400) rose nearly 8% as it reported a revenue of approximately RMB 3.332 billion for Q3 2025, a year-on-year increase of about 22.1% [1] - ZTO Express (02057) saw a rise of over 4% following a report indicating a Q3 revenue and adjusted net profit growth of 11% and 7% year-on-year, respectively [1] - Qiniu Intelligent (02567) increased by 5% due to its core advantage in integrated MPaaS technology, supporting one-stop audio and video solutions [1] Group 2 - HAPO Pharmaceuticals-B (02142) rose nearly 5% after announcing an expanded collaboration with AstraZeneca for new generation biotherapies [2] - Junshi Biosciences (01877) increased by over 5% after achieving primary research endpoints in a clinical study for its drug JS001sc [2] - Dazhong Public Utilities (01635) rose over 8% following the announcement of the successful IPO of Moer Thread, marking a record high issuance price in the A-share market [2] Group 3 - Airline stocks faced declines, with China Eastern Airlines (00670) dropping nearly 6% and China Southern Airlines (01055) down nearly 3% due to a significant increase in flight cancellations to Japan [3] Group 4 - Alibaba-W (09988) increased by over 3% after its app surpassed 10 million downloads within a week of public testing [4] - Xiaomi Group-W (01810) rose over 5% as its founder invested over HKD 100 million to increase his stake to 23.26%, reflecting confidence in the company's growth potential [4] Group 5 - U.S. storage stocks saw collective gains, with SanDisk (SNDK.US) up 13.33% and Western Digital (WDC.US) up 8.43%, following a bullish outlook from Bank of America [5] - Qudian (QD.US) rose 10.3% after reporting a Q3 diluted earnings per ADS of RMB 2.47, exceeding last year's figure [5] - WeRide (WRD.US) surged 14.72% with a 144% year-on-year revenue growth to RMB 171 million for Q3, attributed to fleet expansion [5] Group 6 - Lotus (LOT.US) fell 1.57% after reporting a narrower loss of USD 0.10 per share for Q3, with sales declining to USD 137 million [6] - Chinese concept stocks mostly rose, with HSAI (HSAI.US) up 18.08% and Alibaba (BABA.US) up 5.1%, driven by significant partnerships in the ADAS sector [6] Group 7 - Major tech stocks in the U.S. saw gains, with Google A (GOOGL.US) up 6.31% and Tesla (TSLA.US) up 6.82%, following advancements in AI technology [7]

Core Viewpoint - Heptagon Pharmaceuticals-B (02142) has seen a nearly 5% increase in stock price, currently at HKD 13.62, following the announcement of an expanded collaboration agreement with AstraZeneca PLC aimed at developing next-generation biotherapies, including antibody-drug conjugates (ADC) and T-cell connectors [1]. Company Summary - Heptagon Pharmaceuticals-B's stock price rose by 4.77% to HKD 13.62 with a trading volume of HKD 23.44 million [1]. - The company announced a collaboration, option, and licensing agreement with AstraZeneca PLC on November 24, 2023, which expands the scope of their partnership [1]. - The revised agreement aims to leverage the expertise of both companies to jointly discover and develop new biotherapies [1]. - The economic terms and financial framework established under the collaboration agreement remain consistent with previous agreements [1].

每经AI快讯，和铂医药-B(02142.HK)涨近5%，截至发稿，涨4.92%，报13.62港元，成交额1542.11万港 元。 ...

Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) increased by nearly 5%, reaching HKD 13.62, with a trading volume of HKD 15.42 million following the announcement of a collaboration agreement with AstraZeneca [1] Group 1: Company Developments - On November 24, HAPO Pharmaceutical-B announced that its indirect wholly-owned subsidiary, HAPO Pharmaceutical (Shanghai) Co., Ltd. (HAPO Shanghai), entered into a collaboration, option, and licensing agreement with AstraZeneca PLC [1] - The collaboration aims to expand the scope of their partnership, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers [1] - The economic terms and financial framework established under the collaboration agreement remain consistent with previous agreements [1]